Novo Nordisk A/S: Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency

Posted: June 13, 2022 at 2:35 am

Investigational phase 3 data for Sogroya® (somapacitan) injection in children with growth hormone deficiency presented today at the ENDO 2022 Congress1

Read more here:
Novo Nordisk A/S: Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency

Related Posts